A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of； (a) a much longer duration of action； (b) a much faster rate of onset of muscular paralysis； (c) a significantly greater intramuscular safety margin； (d) a selective action on inhibition of smooth muscle contraction； (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.
